Drug
Bermekimab
Bermekimab is a pharmaceutical drug with 4 clinical trials. Historical success rate of 25.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
25.0%
Based on 1 completed trials
Completion Rate
25%(1/4)
Active Trials
0(0%)
Results Posted
400%(4 trials)
Terminated
3(75%)
Phase Distribution
Ph phase_2
4
100%
Phase Distribution
0
Early Stage
4
Mid Stage
0
Late Stage
Phase Distribution4 total trials
Phase 2Efficacy & side effects
4(100.0%)
Highest Phase Reached
Phase 2Trial Status & Enrollment
Completion Rate
25.0%
1 of 4 finished
Non-Completion Rate
75.0%
3 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(1)
Terminated(3)
Detailed Status
Terminated3
Completed1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
25.0%
Most Advanced
Phase 2
Trials by Phase
Phase 24 (100.0%)
Trials by Status
terminated375%
completed125%
Recent Activity
0 active trials
Showing 4 of 4
terminatedphase_2
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04988308
completedphase_2
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
NCT04019041
terminatedphase_2
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT04990440
terminatedphase_2
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
NCT04791319
Clinical Trials (4)
Showing 4 of 4 trials
NCT04988308Phase 2
A Study of Bermekimab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa
NCT04019041Phase 2
A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa
NCT04990440Phase 2
A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT04791319Phase 2
A Study of Bermekimab (JNJ-77474462) in the Treatment of Participants With Moderate to Severe Atopic Dermatitis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4